Tissue Repair Shares Soar Over 20% on Distribution Deals and Global Expansion Strategy

Sonal Goyal

11 July 2025 11:04 AM AEST

Tissue Repair Shares Soar Over 20% on Distribution Deals and Global Expansion Strategy

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Tissue Repair (ASX: TRP) appoints Advanced Cosmeceuticals to lead national rollout of TR Pro+® in Australia and New Zealand.

The company also signs its first international distribution deal with Amellie and Proud in Thailand, marking the beginning of global expansion.

TRP shares jumped over 20% to AUD 0.26 on 11 July 2025 following the announcement.

Tissue Repair Limited (ASX:TRP) saw its share price rise more than 20% to AUD 0.26 on 11 July 2025 after announcing major commercial milestones, including new distribution partnerships and its move toward large-scale global expansion. The clinical-stage biotech company has signed a multi-year agreement with Advanced Cosmeceuticals Pty Ltd to launch its flagship skin regeneration product TR Pro+® across Australia and New Zealand.

Advanced Cosmeceuticals is a leading aesthetics distributor in the region, with access to over 2,500 clinics and extensive reach through dermatologists, plastic surgeons, pharmacies, and major e-commerce platforms. The agreement will see TR Pro+® rolled out across three core channels: professional clinics, major pharmacy chains such as Priceline and Chemist Warehouse, and direct-to-consumer platforms including Adore Beauty.

TR Pro+® will be available in multiple formats—10g, 30g, 50g, and a 200g professional-use size—targeting both clinical and consumer markets. The deal positions Tissue Repair to transition from a development-stage biotech company into a revenue-generating enterprise, with the national rollout in Australia set to begin with a soft launch before a full-scale release in February 2026.

Tissue Repair CEO Tony Charara said the partnership will fast-track the company’s commercialisation goals, enabling access to patients and clinicians seeking advanced post-procedure care. “This agreement allows us to deliver TR Pro+® to clinicians and patients while laying the foundation for global expansion,” he said.

In parallel with its domestic growth, Tissue Repair has taken its first step into international markets by signing an exclusive distribution agreement with Amellie and Proud Co., Ltd. for the Thai market. The distributor, a key player in Southeast Asia’s premium cosmeceutical industry, will begin marketing the TR Pro+® 10g SKU to top-tier clinics and dermatology professionals in Thailand, with additional formats to follow.

These announcements follow a successful pilot program for TR Pro+® in Australia, which resulted in stronger-than-expected demand and temporary stock shortages in July. The company is now accelerating its commercial manufacturing scale-up, with plans to expand production capacity and prepare for broader global distribution. A preferred manufacturing partner has been selected, with scaled production expected by late 2026.

Meanwhile, Tissue Repair retains global rights for its medical-grade TR Pro+® line targeting acute and chronic wounds. The product is already TGA-listed in Australia for both medical and aesthetic use, and regulatory approvals are being pursued in the U.S. (510(k) pathway), Europe (Class I CE Mark), and additional Asian markets.

Tissue Repair is also developing a new rejuvenating serum powered by its proprietary Glucoprime® technology, with plans to launch the product through Advanced Cosmeceuticals’ platform.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.